Glutathione and Factor V: No Clinical Indication
Glutathione has no established role in the management of factor V deficiency or factor V Leiden thrombophilia and should not be used for these conditions. The available FDA-labeled glutathione products are topical skin-lightening formulations with no systemic anticoagulant or hemostatic indications 1.
Key Clinical Points
Glutathione's Effect on Coagulation Testing
- Glutathione interferes with coagulation laboratory assays but has no therapeutic role in clotting disorders 2
- At concentrations ≥2.5 mg/L, glutathione significantly alters APTT and fibrinogen measurements; at ≥10 mg/L, it affects PT values; and at ≥1250 mg/L, it impacts thrombin time 2
- This represents a laboratory artifact rather than a therapeutic effect—glutathione creates spurious coagulation test results through direct interference with testing reagents 2
FDA-Approved Glutathione Products
- Current FDA-labeled glutathione products contain 1% glutathione combined with ascorbic acid, niacinamide, kojic acid, and sodium hyaluronate 1
- These are topical dermatologic preparations for external use only, specifically formulated for skin lightening 1
- The labeling explicitly warns against systemic use and requires skin testing before application 1
Factor V Leiden Management
Standard Thrombophilia Testing
- Factor V Leiden genetic testing is the appropriate diagnostic approach for suspected APC resistance, not glutathione supplementation 3
- The 2025 ACMG guidelines recommend testing for the factor V Leiden variant (c.1601G>A, p.Arg534Gln) in patients with venous thromboembolism 3
- Routine testing for rare factor V variants (Cambridge, Hong Kong, Liverpool, Nara) is not necessary for VTE patients 3
Anticoagulation Management
- Anticoagulation therapy for VTE in factor V Leiden patients follows standard protocols without glutathione involvement 4
- Management includes DOACs, VKAs with INR monitoring, or LMWH depending on clinical circumstances 4
- The 2018 ASH guidelines address optimal anticoagulation management, monitoring parameters, and reversal strategies—none involve glutathione 4
Critical Caveat
Do not confuse glutathione's laboratory interference with therapeutic benefit. The research showing altered coagulation parameters 2 reflects assay interference that could lead to misdiagnosis or inappropriate treatment adjustments if glutathione is present in patient samples during testing. This is a testing pitfall to avoid, not a treatment opportunity.
Platelet Function in Factor V Leiden
- Recent evidence shows that heterozygous factor V Leiden does not significantly alter platelet aggregation or activation markers during pregnancy compared to non-carriers 5
- Soluble P-selectin increases while platelet aggregation paradoxically decreases during pregnancy, regardless of factor V Leiden status 5